Skip to main content

Advertisement

Fig. 1 | Virology Journal

Fig. 1

From: High sustained virologic response rates of sofosbuvir-based regimens in Chinese patients with HCV genotype 3a infection in a real-world setting

Fig. 1

Study design for HCV genotype 3a infected patients enrolled in the study. Nine patients (including 2 with cirrhosis) were treated with SOF/VEL for 12 weeks, 20 patients (including 2 with cirrhosis) were treated with SOF/DCV for 12 weeks and 12 patients (including 6 with cirrhosis) were treated with SOF/DCV for 24 weeks. All the patients were followed-up for more than 12 weeks after the completion of treatment

Back to article page